AZD2624 Multiple Ascending Dose Study in Japan

NCT00696865 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-07-16

No results posted yet for this study

Summary

This multiple ascending dose study will evaluate safety and tolerability after repeated ascending doses of AZD2624

Conditions

  • Healthy
  • Safety

Interventions

DRUG

AZD2624

oral suspension, 3 doses

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Yuji Kumagai, MD, PhD · Kitasato University East Hospital, Kanagawa, Japan

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Completion
2008-08-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00696865 on ClinicalTrials.gov